Form 8-K

8-K — Barinthus Biotherapeutics plc.

Accession: 0001104659-26-100470

Filed: 2026-08-25

Period: 2026-08-24

CIK: 0001828185

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2623930d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2623930d1_ex99-1.htm)

GRAPHIC (tm2623930d1_ex99-1img01.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2623930d1_8k.htm · Sequence: 1

false

0001828185

00-0000000

NASDAQ

0001828185

2026-08-24

0001828185

VACC:AmericanDepositarySharesMember

2026-08-24

0001828185

us-gaap:CommonStockMember

2026-08-24

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 24, 2026

BARINTHUS BIOTHERAPEUTICS PLC

(Exact name of registrant as specified in its

charter)

England and Wales

001-40367

Not Applicable

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

c/o Barinthus Biotherapeutics plc

20400 Century Boulevard, Suite 210

Germantown,

MD 20874

United States of America

(Address of principal executive offices, including

zip code)

(443) 917-0966

(Registrant’s telephone number, including

area code)

Not Applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trade Symbol(s)

Name of each exchange on which

registered

American Depositary Shares

BRNS

The Nasdaq Global Market

Ordinary shares, nominal value £0.000025 per share*

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ¨

American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) ordinary

share. Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Market. The American

Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended,

pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation

of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8.

00-0000000

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued

Listing Rule or Standard; Transfer of Listing.

On August 24, 2026, in connection with the

scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the “Scheme”), which is expected to become effective

on September 3, 2026 and is contemplated by the Agreement and Plan of Merger, dated September 29, 2025, by and among Barinthus Biotherapeutics

plc (the “Company”), Beacon Topco, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Topco”),

Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware

corporation (as amended, the “Merger Agreement”), the Company notified The Nasdaq Stock Market, LLC (“Nasdaq”)

of its intent to withdraw the listing of the Company’s American Depositary Shares (the “ADSs”) from Nasdaq following

the effectiveness of the Scheme and requested Nasdaq file a Notification of Removal from Listing and/or Registration on Form 25 with the

Securities and Exchange Commission (the “SEC”) to delist the ADSs from Nasdaq and deregister the ADSs under Section 12(b)

of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Upon effectiveness of the Form 25, the Company intends

to file with the SEC a Form 15 under the Exchange Act, requesting the deregistration of the ADSs and the suspension of the Company’s

reporting obligations under Sections 13 and 15(d) of the Exchange Act. Trading of the ADSs on Nasdaq is expected to halt prior to the

opening of trading on September 3, 2026. Following the completion of the transactions contemplated by the Merger Agreement, Topco will

be renamed “Clywedog Therapeutics Holdings, Inc.,” and its common stock will be listed on Nasdaq under the ticker symbol “CLYD.”

Item 7.01. Regulation FD Disclosure.

On August 24, 2026, the Company issued a press release titled “Barinthus

Bio Provides Update on Proposed Combination with Clywedog Therapeutics.” A copy of the press release is furnished as Exhibit 99.1

to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K (including

Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise

subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the

Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01. Other Events.

On August 24, 2026, pursuant to the terms

of the Merger Agreement, the board of directors of the Company (the “Board”) determined that the Scheme Exchange Ratio (as

defined in the Merger Agreement) is 0.111, which ensures that the price of the shares of Topco's common stock to be issued in exchange for the Scheme Shares (as defined in the

Merger Agreement) would be sufficient to satisfy the minimum price requirement appliable to the listing of Topco's common stock on Nasdaq.

The Merger Exchange Ratio (as defined in the

Merger Agreement) will be determined as of immediately prior to the closing of the merger based on the Scheme Exchange Ratio as finally

determined by the Board, any adjustments as provided in the Merger Agreement and to maintain the agreed ownership split of Topco following

closing of the transaction.

The Company’s application in respect

of the transactions contemplated within the Merger Agreement is directed to be heard before a High Court Judge at the Royal Courts of

Justice, The Rolls Building, 7 Rolls Building, Fetter Lane, London, United Kingdom, EC4A 1NL on September 1, 2026.

Forward Looking Statements

This Current Report on Form 8-K contains

forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally

be identified as such by use of the words “expect,” “will,” and similar expressions, although not all forward-looking

statements contain these identifying words. These forward-looking statements include, without limitation, express or implied statements

regarding the expected effectiveness and timing of the Scheme, the expected timing of the suspension of trading, delisting and deregistration

of the ADSs, and the determination of the Merger Exchange Ratio. Any forward-looking statements in this Current Report on Form 8-K

are based on management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important factors

that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained

in this Current Report on Form 8-K, including, without limitation, risks and uncertainties related to the success, cost and timing

of the Company’s pipeline development activities and planned and ongoing clinical trials, the Company’s ability to execute

on its strategy, regulatory developments, the risk that the Company may not achieve the anticipated benefits of its pipeline prioritization

and corporate restructuring, the Company’s ability to fund its operations and access capital, the Company’s preliminary estimates

of its cash and cash equivalents, including the risk that final financial results may differ materially from the Company’s preliminary

estimates, the risk that the proposed transaction contemplated by the Merger Agreement may not be completed in a timely manner or at all,

which may adversely affect our business and the price of our securities, the risk that that the proposed transaction may involve unexpected

costs, liabilities or delays, or divert management’s attention from our ongoing business operations, the risk of any legal proceedings

related to the proposed transaction or otherwise, or the impact of the proposed transaction thereupon, the risk that the anticipated benefits

of the proposed transaction may otherwise not be fully realized or may take longer to realize than expected, risks relating to the value

of the combined company securities to be issued in the proposed transaction, and other risks identified in the Company’s filings

with the Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended

December 31, 2025, its Quarterly Reports on Form 10-Q and subsequent filings with the SEC. The Company cautions you not to place

undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any obligation

to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which

any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking

statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1

Press Release dated August 24, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 25, 2026

Barinthus Biotherapeutics

plc

By:

/s/

William Enright

Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2623930d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Barinthus

Bio Provides Update on Proposed Combination with Clywedog Therapeutics

• Scheme

Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement

• Scheme

of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs

expected to cease trading on Nasdaq prior to market open

• Topco

common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD”

following completion of the proposed combination with Clywedog

GERMANTOWN, Maryland, August 24, 2026

(GLOBE NEWSWIRE) – Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today

provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. (“Clywedog”)

in an all-stock transaction.

Notice of

Delisting and Transfer of Listing.

On August 24,

2026, in connection with the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the “Scheme”),

which is expected to become effective on September 3, 2026 and is contemplated by the Agreement and Plan of Merger, dated September 29,

2025, by and among the Company, Beacon Topco, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Topco”),

Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog (as amended, the “Merger

Agreement”), the Company notified The Nasdaq Stock Market, LLC (“Nasdaq”) of its intent to withdraw the listing of

the Company’s American Depositary Shares (the “ADSs”) from Nasdaq following the effectiveness of the Scheme and requested

Nasdaq file a Notification of Removal from Listing and/or Registration on Form 25 with the Securities and Exchange Commission (the “SEC”)

to delist the ADSs from Nasdaq and deregister the ADSs under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange

Act”). Upon effectiveness of the Form 25, the Company intends to file with the SEC a Form 15 under the Exchange Act, requesting

the deregistration of the ADSs and the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange

Act. Trading of the ADSs on Nasdaq is expected to halt prior to the opening of trading on September 3, 2026. Following the completion

of the transactions contemplated by the Merger Agreement, Topco will be renamed “Clywedog Therapeutics Holdings, Inc.,” and

its common stock will be listed on Nasdaq under the ticker symbol “CLYD.”

Determination

of the Scheme Exchange Ratio

On August 24,

2026, pursuant to the terms of the Merger Agreement, the board of directors of the Company (the “Board”) determined that

the Scheme Exchange Ratio (as defined in the Merger Agreement) is 0.111, which ensures that the price of the shares in Topco's common stock to be issued in exchange for the Scheme Shares (as defined in the

Merger Agreement) would be sufficient to satisfy the minimum price requirement appliable to the listing of Topco's common stock on Nasdaq.

The Merger

Exchange Ratio (as defined in the Merger Agreement) will be determined as of immediately prior to the closing of the merger based on

the Scheme Exchange Ratio as finally determined by the Board, any adjustments as provided in the Merger Agreement and to maintain the

agreed ownership split of Topco following closing of the transaction.

Announcement

of Date of Hearing

The Company’s

application in respect of the transactions contemplated within the Merger Agreement is directed to be heard before a High Court Judge

at the Royal Courts of Justice, The Rolls Building, 7 Rolls Building, Fetter Lane, London, United Kingdom, EC4A 1NL on September 1, 2026.

About Barinthus Bio

Barinthus Biotherapeutics (NASDAQ:

BRNS) is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates designed to guide the immune system

to overcome autoimmunity and chronic infectious diseases. Helping people and their families living with serious diseases is the guiding

principle at the heart of Barinthus Bio. With a focused pipeline built around its proprietary platform technologies, Barinthus Bio is

advancing immunotherapeutic product candidates in autoimmunity including: VTP-1000, which utilizes the Company's SNAP-Tolerance Immunotherapy

(SNAP-TI) platform and is designed to treat people with celiac disease. Barinthus Bio’s differentiated technology platform and

therapeutic approach, coupled with deep scientific expertise and focus on clinical development, positions the Company to navigate towards

delivering treatments that improve the lives of people with autoimmunity. For more information, visit www.barinthusbio.com.

Forward Looking Statements

This press release contains forward-looking

statements regarding Barinthus Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can

generally be identified as such by use of the words “may,” “will,” “plan,” “forward,”

“encouraging,” “believe,” “potential,” “expect,” and similar expressions, although not

all forward-looking statements contain these identifying words. These forward-looking statements include, without limitation, express

or implied statements regarding the expected effectiveness and timing of the Scheme, the expected timing of the suspension of trading,

delisting and deregistration of the ADSs, and the determination of the Merger Exchange Ratio. Any forward-looking statements in this

press release are based on management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important

factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements

contained in this press release, including, without limitation, risks and uncertainties related to the success, cost and timing of the

Company’s pipeline development activities and planned and ongoing clinical trials, including the risk that the timing for preliminary,

interim or final data or initiation of clinical trials may be delayed, the risk that interim or topline data may not reflect final data

or results, the Company’s ability to execute on strategy, regulatory developments, the risk that the Company may not achieve the

anticipated benefits of our pipeline prioritization and corporate restructuring, the Company’s ability to fund its operations and

access capital, the Company’s cash runway, including the risk that the estimate of the cash runway may be incorrect, the risk that

the proposed transaction may not be completed in a timely manner or at all, which may adversely affect our business and the price of

our securities, the risk that that the proposed transaction may involve unexpected costs, liabilities or delays, or divert management’s

attention from our ongoing business operations, the risk of any legal proceedings related to the proposed transaction or otherwise, or

the impact of the proposed transaction thereupon, the risk that the anticipated benefits of the proposed transaction may otherwise not

be fully realized or may take longer to realize than expected, risks relating to the value of the combined company securities to be issued

in the proposed transaction, the risks associated with global economic uncertainty, including disruptions in the banking industry, the

conflicts in Ukraine, Iran, Israel and Gaza, the disruptions in U.S. federal government operations, tariffs imposed by the U.S. and other

countries, and the other risks identified in the Company’s filings with the Securities and Exchange Commission (the “SEC”),

including the Company’s most recent annual report on Form 10-K and subsequent filings the Company may make with the SEC. The Company

cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company

expressly disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events,

conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ

from those set forth in the forward-looking statements.

Additional Information and Where

to Find It

In connection with the proposed transaction,

the combined company plans to file with the SEC and mail or otherwise provide to Barinthus Bio's investors and security holders a registration

statement on Form S-4 that will contain a joint proxy statement/prospectus (the “Registration

Statement”). BARINTHUS BIO’S INVESTORS AND SECURITY HOLDERS ARE URGED TO CAREFULLY

READ THE REGISTRATION STATEMENT IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS FILED BY BARINTHUS BIO WITH THE SEC

IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT

THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION.

Investors and security holders may obtain

a free copy of the Registration Statement and other documents that the combined company files with the SEC (when available) from the

SEC’s website at www.sec.gov or at investors.barinthusbio.com.

No Offer or Solicitation

This press release is not intended to

and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, nor shall there be any

offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration

or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus

meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Participants in the Solicitation

Clywedog, Barinthus Bio and their respective

directors, executive officers, other members of management, certain employees and other persons may be deemed to be participants in the

solicitation of proxies from the security holders of Barinthus Bio in connection with the proposed transaction. Security holders may

obtain information regarding the names, affiliations and interests of Barinthus Bio’s

directors and executive officers in Barinthus Bio’s Annual Report on Form 10-K for

the fiscal year ended December 31, 2025, which was filed with the SEC on March 13, 2026. To the extent holdings of Barinthus Bio’s

securities by Barinthus Bio’s directors and executive officers have changed since

the amounts set forth in such Annual Report on Form 10-K, such changes have been or will be reflected on subsequent Statements of Changes

in Beneficial Ownership on Form 4 filed with the SEC. Additional information regarding the interests of such individuals in the proposed

transaction will be included in the Registration Statement relating to the proposed transaction when it is filed with the SEC. These

documents (when available) may be obtained free of charge from the SEC’s website at www.sec.gov and

Barinthus Bio’s website at investors.barinthusbio.com.

Company contact:

ir@barinthusbio.com

GRAPHIC

Filename: tm2623930d1_ex99-1img01.jpg · Sequence: 3

Binary file (7471 bytes)

Download tm2623930d1_ex99-1img01.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Aug. 24, 2026

Document Information [Line Items]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 24, 2026

Entity File Number

001-40367

Entity Registrant Name

BARINTHUS BIOTHERAPEUTICS PLC

Entity Central Index Key

0001828185

Entity Tax Identification Number

00-0000000

Entity Incorporation, State or Country Code

Entity Address, Address Line One

c/o Barinthus Biotherapeutics plc

Entity Address, Address Line Two

20400 Century Boulevard

Entity Address, Address Line Three

Suite 210

Entity Address, City or Town

Germantown

Entity Address, State or Province

Entity Address, Country

Entity Address, Postal Zip Code

20874

City Area Code

443

Local Phone Number

917-0966

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

American Depositary Shares [Member]

Document Information [Line Items]

Title of 12(b) Security

American Depositary Shares

Trading Symbol

BRNS

Security Exchange Name

NASDAQ

Common Stock [Member]

Document Information [Line Items]

Title of 12(b) Security

Ordinary shares, nominal value £0.000025 per share*

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=VACC_AmericanDepositarySharesMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: